Literature DB >> 23033160

An evidence base for noradrenergic deficits in Parkinson's disease.

Glenda Halliday.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23033160     DOI： 10.1002/mds.25202

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  3 in total

1.  Predictive model of spread of Parkinson's pathology using network diffusion.

Authors:  S Pandya; Y Zeighami; B Freeze; M Dadar; D L Collins; A Dagher; A Raj
Journal:  Neuroimage       Date:  2019-03-06       Impact factor: 6.556

2.  Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.

Authors:  Lei-Fang Cao; Xiao-Yan Peng; Ya Huang; Bing Wang; Feng-Ming Zhou; Ruo-Xiao Cheng; Li-Hua Chen; Wei-Feng Luo; Tong Liu
Journal:  Neural Plast       Date:  2016-09-26       Impact factor: 3.599

3.  Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis.

Authors:  Charlotte M Ermine; Jordan L Wright; Stefano Frausin; Jessica A Kauhausen; Clare L Parish; Davor Stanic; Lachlan H Thompson
Journal:  Hippocampus       Date:  2018-02-24       Impact factor: 3.899
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.